Is it safe to preserve uterus after live birth following progestin‐based fertility‐sparing treatment for endometrial cancer or atypical hyperplasia: A long‐term retrospective cohort study
Acta Obstetricia et Gynecologica Scandinavica · 2026
DOI: 10.1111/aogs.70139 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2026. Verfasst von Yiqin Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Endometrial Hyperplasia, Fertility Preservation, Endometrial Neoplasms, Progestins. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Major Projects of National Science and Technology, Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
We aimed to assess the safety of continuous uterus‐preserving treatment among patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) who gave birth after progestin‐based fertility‐sparing treatment (FST). Material and Methods From January 2005 to June 2020, we conducted a retrospective cohort study at Peking University People's Hospital, China, comprising 212 patients with EC or AEH who underwent FST. The participants were categorized into two groups based on the reproductive outcome of live birth. Risk factors were analyzed for disease recurrence in the entire cohort, and additional analysis was conducted on postpartum recurrence specifically in the live birth group.
Results
Of 212 eligible patients, 73 had a live birth, and 139 did not have a live birth after FST. Multivariable Cox analysis showed that live birth significantly reduced the risk of disease recurrence (HR 0.326, p = 0.011), while insulin resistance was identified as an adverse factor (HR 3.216, p = 0.014). Except for two patients who underwent hysterectomy, among 71 patients undergoing uterus preservation after live birth, five (7%) patients experienced disease relapse (two EC and three AEH) after a median follow‐up of 26 (11, 47.5) months. Four out of these five patients with recurrence achieved a complete response after a second round of FST. Eight other patients (11.3%) experienced hyperplasia without atypical (EH) after live birth. Potential risk factors for postpartum recurrence of EC/AEH included irregular menstruation (80% vs. 39%; p = 0.153), abnormal ultrasonographic findings (60% vs. 18.6%; p = 0.065), and increased endometrial thickness (0.82 cm vs. 0.55 cm; p = 0.017). While postpartum maintenance therapy was identified as a protective factor against recurrence (0% vs. 62.5%; p = 0.012). Notably, patients with postpartum recurrence may achieve a complete response with repeat FST.
Conclusions
Although live birth was associated with improved recurrence‐free survival in patients with EC or AEH receiving FST, postpartum recurrence remains a concern. Irregular menstruation and abnormal ultrasound findings were identified as key risk factors for recurrence, while maintenance therapy exhibited a protective effect. These findings highlight the need for vigilant postpartum monitoring in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.
- Clinical Research Institute, Peking University, Beijing, China.
- Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Yiqin Wang, Qun Lu
Förderung
- Major Projects of National Science and Technology
- Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, Y., Liu, Y., Feng, Y., Bo, L., Xiao, Z., Wang, H., Tian, L., Lu, Q., Zhou, R., & Wang, J. (2026). Is it safe to preserve uterus after live birth following progestin‐based fertility‐sparing treatment for endometrial cancer or atypical hyperplasia: A long‐term retrospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70139
Vancouver
Wang Y, Liu Y, Feng Y, Bo L, Xiao Z, Wang H, et al. Is it safe to preserve uterus after live birth following progestin‐based fertility‐sparing treatment for endometrial cancer or atypical hyperplasia: A long‐term retrospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70139
BibTeX
@article{Wang2026,
author = {Wang, Yiqin and Liu, Yuanyuan and Feng, Yifan and Bo, Linlin and Xiao, Zerui and Wang, Haibo and Tian, Li and Lu, Qun and Zhou, Rong and Wang, Jianliu},
title = {Is it safe to preserve uterus after live birth following progestin‐based fertility‐sparing treatment for endometrial cancer or atypical hyperplasia: A long‐term retrospective cohort study},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
doi = {10.1111/aogs.70139}
}
EUVIMED